LLY
Eli Lilly and Company
LLY's fundamentals are strong: revenue grew 46% and it turned 23% of its revenue into free cash flow. At 46x earnings, it's trading in line with its usual 48x. Analysts expect that strong growth to continue.
NTLA
Intellia Therapeutics, Inc.
There isn't enough reported data to score NTLA yet.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
NTLA Fundamentals
| Metric | Status |
|---|---|
| Under pressure | |
| Under pressure | |
| Under pressure | |
| Unavailable |
NTLA's revenue, profitability and cash flow are currently under pressure. There isn't enough data to rate its balance sheet.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY's PE is in its fair range at 46x. If earnings grow as analysts expect, today's price would be 30x next year's earnings, in its cheap range.
NTLA PE Valuation
NTLA has no meaningful PE right now: it lost money over the past year.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for LLY, with profitability improving.
NTLA Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Strong growth | |
| -- | |
| Limited | |
| Low |
Analysts expect NTLA's losses to shrink, with revenue growing. However, they disagree widely on these estimates.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.82 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY has the edge over NTLA on earnings quality, reporting a profit while its opponent remains loss making.
NTLA Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$3.33 | +$0.94 |
| Q2 2026 | -$3.34 | +$1.35 |
| Q1 2026 | -$3.52 | +$1.71 |
| Q4 2025 | -$3.81 | +$1.44 |
| Q3 2025 | -$4.27 | +$1.17 |
| Q2 2025 | -$4.69 | +$0.79 |
| Q1 2025 | -$5.23 | +$0.13 |
| Q4 2024 | -$5.25 | +$0.16 |
NTLA is still losing money, but less than at its worst: $3.33 per share over the past year, against $6.16 at its worst in late 2022.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY has the edge over NTLA on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY has the edge over NTLA on profitability, with a higher operating margin.
NTLA Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $7.2M | -48% |
| Q2 2026 | $7.7M | -46% |
| Q1 2026 | $15M | -9.5% |
| Q4 2025 | $23M | +79% |
| Q3 2025 | $13.8M | +51% |
| Q2 2025 | $14.2M | +105% |
| Q1 2025 | $16.6M | -43% |
| Q3 2024 | $9.1M | -24% |
NTLA's revenue has slid since its 2024 peak: $7M last quarter, down 48% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -1708% | -899 points |
| Q2 2026 | -1472% | -700 points |
| Q1 2026 | -668% | +59 points |
| Q4 2025 | -429% | +631 points |
| Q3 2025 | -809% | +780 points |
| Q2 2025 | -772% | +1226 points |
| Q1 2025 | -727% | -333 points |
| Q4 2024 | -1060% | N/A |
NTLA's operating margin was −1708% last quarter, down 899 points from the same quarter a year ago, near the bottom of its range since 2019.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY has the edge over NTLA on cash generation, producing positive trailing cash flow while its opponent burns cash.
NTLA Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$86.3M | -$9.4M |
| Q2 2026 | -$84.9M | +$14.9M |
| Q1 2026 | -$117.4M | +$32.2M |
| Q4 2025 | -$69.4M | +$16.8M |
| Q3 2025 | -$76.9M | +$9.2M |
| Q2 2025 | -$99.9M | -$40.7M |
| Q1 2025 | -$149.7M | -$26.5M |
| Q4 2024 | -$86.2M | +$8.4M |
NTLA has burned cash in almost every quarter: −$358M over the past year, against −$413M the year before.
LLY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -300K shares |
| 1 year | -0.6% | -5.4M shares |
| 3 years | -0.7% | -6.4M shares |
| 5 years | -1.9% | -17.4M shares |
| Available history | -4.5% | -42.3M shares |
LLY has the edge over NTLA on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $377M |
| Q2 2026 | $1.6B |
| Q1 2026 | $2.4B |
| Q4 2025 | $1.5B |
| Q3 2025 | $708.1M |
| Q2 2025 | $692.2M |
| Q1 2025 | $1.2B |
| Q4 2024 | $2.1B |
LLY spent $5.8B buying back its own shares over the past year, up 26% from the year before.
NTLA Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +5% | +6.7M shares |
| 1 year | +27% | +30M shares |
| 3 years | +58% | +51.5M shares |
| 5 years | +106% | +72M shares |
| Available history | +184% | +90.8M shares |
NTLA has 140M diluted shares, up 27% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2023 | — |
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY's net debt is about 1.2 years of its operating earnings (EBITDA), about the same as a year ago.
NTLA Net Leverage
NTLA's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
NTLA Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 42.6 | Neutral |
| Stochastic | 30.2 | Neutral |
NTLA's weekly RSI is 43 (neutral) and its Stochastic is 30 (neutral).
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY is trading at 46x earnings, a 79% premium to the Healthcare sector's median of 26x.
NTLA PE vs Healthcare Sector
NTLA has no meaningful PE right now: it lost money over the past year.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY has the edge over NTLA on trend strength, trading above more of its moving averages.
NTLA Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $11.8 | 10% below |
| 20 week MA | $12.2 | 14% below |
| 50 week MA | $12.5 | 16% below |
| 100 week MA | $11.9 | 11% below |
| 200 week MA | $20.8 | 49% below |
NTLA is in a downtrend: it's below all five of its weekly moving averages, and 49% below its 200-week average.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has the edge over NTLA on returns for 2026, with the stronger performance.
NTLA Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $15.4 | $62.1 | +304% |
| 2021 | $62.1 | $126.8 | +104% |
| 2022 | $126.8 | $35.0 | -72% |
| 2023 | $35.0 | $30.5 | -13% |
| 2024 | $30.5 | $12.0 | -61% |
| 2025 | $12.0 | $9.44 | -21% |
| 2026 YTD | $9.44 | $10.6 | +12% |
NTLA has finished four years in a row lower, and it's up 12% so far in 2026.